semaglutide label may reduce opioid overdoses, a new study suggests behavior change Semaglutide 0.25mg for Weight Loss:

Long-Term Research Considerations Research suggests that the long-term safety profile requires further investigation through extended studies and careful observation protocols

Within 24 hours of injecting the first dose of a weight-loss medication she received following a visit with a telehealth doctor, Karleigh McClain was admitted to the hospital, she said

The current evidence base for GLP-1 receptor agonist therapy is derived from extensive clinical trial programmes that have established the efficacy and safety of specific, licensed doses

LocciAPorcuPTalaniGSantoruFBerrettiRGiuntiEet al

doi: 10.1038/nature12721 45 GaoK.YangR.ZhangJ.WangZ.JiaC.ZhangF.et al